BTIG Research Boosts Masimo (NASDAQ:MASI) Price Target to $170.00

Masimo (NASDAQ:MASI) had its price target upped by BTIG Research from $166.00 to $170.00 in a research report report published on Monday, Benzinga reports. BTIG Research currently has a buy rating on the medical equipment provider’s stock.

Several other equities analysts have also recently issued reports on the stock. Piper Sandler boosted their target price on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $145.33.

Masimo Stock Up 0.4 %

Shares of MASI stock opened at $144.56 on Monday. The stock has a market cap of $7.69 billion, a P/E ratio of 98.34 and a beta of 0.99. The company’s fifty day simple moving average is $125.01 and its two-hundred day simple moving average is $125.12. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. Masimo has a 52 week low of $75.22 and a 52 week high of $153.93.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The company had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. During the same quarter last year, the business posted $0.62 EPS. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. Analysts predict that Masimo will post 3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Riverview Trust Co purchased a new stake in Masimo in the 1st quarter valued at about $25,000. NBC Securities Inc. lifted its stake in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its position in shares of Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 573 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.